

REVIEW ARTICLE

Microbial Biosynthesis of Novel Bioactive Compounds

¹Brahmam Pasumarthi, ²Ram Babu, ³Kavita Chahal, ⁴T. Kiranmai, ⁵D. Jayarajan

¹Dept of Humanities and Sciences, PACE Institute of Technology and Sciences, Ongole, Prakasam District, Andhra Pradesh, India.

²Department of Botany, Kirori Mal College, University of Delhi, Delhi 110007

³Govt. Science College Jabalpur, Madhya Pradesh, India

⁴Lecturer in Botany, Maris Stella College (Autonomous) Vijayawada, NTR district, Andhra Pradesh, India

⁵Head of Dept. Medical Lab Technology, Divine Mother College, Korkadu, Puducherry, TN

Email: brahmampp147@gmail.com/ asairaj123@gmail.com

ABSTRACT

Microbial biosynthesis is a valuable source of bioactive molecules that have various chemical structures and pharmacological effects. This gives great opportunities for discovering new drugs, advancing agricultural practices, and enhancing industrial biotechnology. This comprehensive review consolidates current progress in microbial biosynthesis research, with a specific emphasis on the complex interaction between microbial diversity, synthetic biology, and metagenomics in the pursuit of innovative bioactive chemicals. Metagenomics has greatly transformed our comprehension of microbial ecosystems by allowing us to study microorganisms that cannot be grown in a lab and uncovering hidden gene clusters responsible for producing previously undiscovered natural chemicals. Metagenomic research have revealed the ability of many ecosystems, including terrestrial soils, marine sediments, hydrothermal vents, and polar locations, to produce a wide range of substances by using bioinformatics tools and high-throughput sequencing technology. By employing focused screening and functional metagenomics techniques, scientists may detect biosynthetic gene clusters and forecast the chemical compositions of bioactive chemicals, therefore broadening the range of microbial bioprospecting. Synthetic biology has become a potent method for modifying and improving microbial hosts to boost their ability to produce desired substances. Synthetic biologists may edit and construct biosynthetic gene clusters to produce complex natural products and their derivatives by using modular genetic components and pathway engineering methodologies. The use of CRISPR-Cas9-mediated genome editing, pathway optimisation, and heterologous expression systems enables the creation of customised microbial strains that have the ability to produce valuable chemicals with enhanced yields and attributes. In addition, synthetic biology platforms allow the investigation of biosynthetic variety by employing combinatorial biosynthesis and enzyme engineering methods. This ultimately results in the development of new chemical compounds that possess customised pharmacological characteristics. The microbial biosynthesis process produces a variety of bioactive molecules that exhibit structural diversity. These compounds belong to several chemical classes such as polyketides, nonribosomal peptides, terpenoids, and alkaloids. These compounds display a wide range of pharmacological actions, such as antibacterial, anticancer, antiviral, anti-inflammatory, and enzyme inhibitory characteristics. Moreover, chemicals originating from microorganisms are ideal starting points for discovering new drugs. They provide unique chemical structures and modes of action that may be used to develop therapies for a wide range of illnesses and disorders. Although significant advancements have been achieved in the field of microbial biosynthesis research, there are still some obstacles that need to be overcome in order to fully exploit the capabilities of microbial-derived molecules. Current research focuses on optimising fermentation methods, understanding biosynthetic pathways, and developing scalable production systems. Furthermore, the process of translating microbial-derived drugs from the stage of discovery to commercialization necessitates the resolution of challenges pertaining to formulation, stability, and obtaining regulatory approval. Microbial biosynthesis has great potential for identifying and creating new bioactive chemicals that may be used in both medicinal and industrial settings. Researchers may harness the extensive metabolic capabilities of microorganisms and tackle important social issues by combining microbial diversity, synthetic biology, and metagenomics techniques. The future growth in multidisciplinary research and technical innovation is expected to speed up the process of discovering, producing, and commercialising substances produced from microbes. This will drive breakthroughs in drug discovery, agriculture, and industrial biotechnology.

Keywords: Microbial biosynthesis, Bioactive compounds, Synthetic biology, Metagenomics, Natural product discovery, Pathway engineering, Pharmacological activities, Biosynthetic gene clusters, High-throughput sequencing, Metabolic pathways

How to cite this article:

Brahmam P, Ram B, Kavita C, T. Kiranmai, D. Jayarajan. Microbial Biosynthesis of Novel Bioactive Compounds. *Adv. Biores.*, Vol 15 (2) March 2024: 409-421.

INTRODUCTION

Microbial biosynthesis is the complicated process in which microbes build intricate organic molecules through enzyme pathways. This process has become crucial in the search for new bioactive substances that may be used in therapy and industry. Microbial-derived chemicals, such as antibiotics, anticancer medicines, enzyme inhibitors, and immunomodulators, are still playing a crucial role in driving innovation in drug development and biotechnology (1). This introduction provides a foundation for a thorough examination of microbial biosynthesis, emphasising current progress, difficulties, and future possibilities in the subject. The immense variety of microorganisms on Earth spans a wide range of metabolic capacities, providing an unmatched source for the exploration of natural products. Bacteria, fungi, actinomycetes, and marine microorganisms, among other organisms, possess complex biosynthetic systems that may produce a wide range of secondary metabolites (2). These compounds frequently have sophisticated chemical structures and powerful biological effects. Secondary metabolites, sometimes referred to as natural products, have traditionally been a valuable source of inspiration for the discovery of drugs. They have provided initial leads for the development of therapies that target a diverse array of illnesses and disorders. The emergence of metagenomics in recent years has significantly transformed our comprehension of microbial biodiversity and the capacity for biosynthesis. Metagenomic techniques, which entail the direct sequencing and analysis of DNA obtained from environmental samples, have facilitated the investigation of microbial communities in a wide range of habitats, such as soil, marine sediments, and severe settings (3). Through the analysis of metagenomic data, scientists might discover biosynthetic gene clusters that contain unique natural compounds, thus broadening the possibilities of exploring microbial resources beyond isolated cultures. Synthetic biology has become a potent tool for the manipulation and enhancement of microbial metabolic pathways. Synthetic biology is a multidisciplinary discipline that combines ideas from biology, engineering, and computer science to create new biological systems with specific functionalities. Synthetic biology techniques, like as CRISPR-Cas9-mediated genome editing, pathway engineering, and combinatorial biosynthesis, allow for the manipulation and construction of biosynthetic gene clusters (4). This enables the creation of intricate natural compounds and their derivatives in different hosts. Moreover, synthetic biology systems have prospects for developing customised molecules with specific pharmacological characteristics, thereby enabling precise drug design and enhancement. The microbial-derived molecules exhibit a broad array of chemical classes, such as polyketides, nonribosomal peptides, terpenoids, and alkaloids, showcasing their structural diversity (5). These compounds demonstrate a wide range of pharmacological actions, including antibacterial, anticancer, antiviral, anti-inflammatory, and enzyme inhibitory characteristics. As a result, they are highly important for drug discovery and development. In addition, chemicals originating from microorganisms frequently operate as starting points for the creation of new therapeutic drugs, offering unique chemical structures and methods of operation for addressing medical conditions that lack effective treatments. Although there has been notable advancement in microbial biosynthesis research, there are still some obstacles that need to be overcome in order to fully exploit the capabilities of microbial-derived molecules. Continual research is being conducted to optimise fermentation conditions, clarify biosynthetic routes, and ensure the scalability of manufacturing systems (6). In addition, the process of translating microbial-derived drugs from the stage of discovery to commercialization necessitates the resolution of challenges pertaining to formulation, stability, and obtaining regulatory approval. This study aims to offer a thorough examination of microbial biosynthesis as a framework for the exploration and advancement of innovative bioactive chemicals. We will examine the methods used to utilise the variety of microorganisms and synthetic biology for the purpose of searching for valuable resources and discovering drugs (7). Additionally, we will clarify the range of different structures and pharmacological effects of compounds derived from microorganisms, and we will address the current difficulties and potential future developments in this field. By combining several fields of study and utilising technological advancements, we can fully utilise the capabilities of microbial biosynthesis to make progress in the fields of health, agriculture, and industry.

Objective and overview of the paper

In this pivotal section, we lay the groundwork for our paper by delineating its overarching objectives and providing an expansive overview of the multifaceted topics to be addressed. Through a meticulous delineation of our aims and the scope of our exploration, we aim to contextualize the subsequent

discussions within the broader landscape of microbial biosynthesis research, emphasizing its pivotal role in the realms of natural product discovery, drug development, and industrial biotechnology.

Objectives:

1. In-depth Investigation of Microbial Biosynthesis:

Our primary goal is to conduct a thorough investigation of microbial biosynthesis, shedding light on its complex mechanisms and clarifying its significant significance for several scientific fields. Through the exploration of various types of microorganisms, the processes they use to produce substances, techniques in the field of synthetic biology, and methodologies including the study of genetic material from entire microbial communities, our goal is to offer a comprehensive grasp of the present state of this discipline.

2. Emphasising Recent Progress and State-of-the-Art Technologies:

Our goal is to highlight the most recent breakthroughs and innovative technologies that have advanced research in microbial biosynthesis. We seek to understand how advancements in high-throughput sequencing, bioinformatics studies, and genome editing technologies like CRISPR-Cas9 have transformed our capacity to investigate, control, and use microbial metabolic networks.

3. Investigation of the Range of Structural Variations and Pharmacological Effects:

Another important goal is to explore the range of different structures found in bioactive chemicals produced by microbial biosynthesis and understand their pharmacological effects. Our objective is to uncover the complex connections between chemical structure and biological function by thoroughly examining polyketides, nonribosomal peptides, terpenoids, alkaloids, and other chemical families (8). In doing so, we want to emphasise the therapeutic possibilities of these molecules.

4. Tackling Obstacles and Mapping Out Future Paths:

Moreover, we strive to tackle the numerous difficulties facing microbial biosynthesis research and establish a path for future exploration and innovation. Our goal is to promote a detailed knowledge of the challenges that hinder progress in fermentation optimisation, route elucidation, scalability, and translational research. We also seek to provide creative ways to overcome these constraints.

Overview of Topics:

1. Microbial Diversity and Biosynthetic Pathways:

This topic explores the variety of microorganisms and the pathways they use to produce various compounds. We begin our voyage by examining the extensive range of microbial variety, which includes bacteria, fungus, actinomycetes, and marine organisms. We explore the complex biosynthetic pathways that are responsible for the creation of bioactive chemicals, uncovering the genetic and enzymatic processes that control their synthesis.

2. Metagenomics and Bioprospecting

Now, we will explore the field of metagenomics, where we will uncover the secrets of microbial communities that live in various habitats. By utilising metagenomic techniques, we are able to discover previously unknown biosynthetic gene clusters and identify new natural compounds that have the potential to be used in therapy. This expands the possibilities for bioprospecting efforts.

3. Synthetic Biology and Pathway Engineering:

We are continuing our journey by exploring the field of synthetic biology, which involves using genetic engineering to modify microbial hosts in order to improve their ability to produce desired substances. By employing genome editing, pathway optimisation, and combinatorial biosynthesis methodologies, we have the ability to create customised microbial factories that can produce intricate natural products.

4. Structural Diversity and Pharmacological Activities:

Next, we begin a journey into the field of structural diversity, where we investigate the complex structures of chemicals originating from microorganisms and decipher their pharmacological effects. We explore a wide range of bioactive compounds, including antimicrobial peptides and anticancer polyketides, to understand their various mechanisms of action and potential for use in therapy.

5. Challenges and Future Directions:

Ultimately, our journey concludes with a thoughtful examination of the obstacles and possibilities that await us in the field of microbial biosynthesis research. We want to map out a direction for future inquiry and innovation in the dynamic field of fermentation optimisation, route elucidation, scaling challenges, and translational research barriers through an honest examination.

Through this extensive exploration of microbial biosynthesis, our goal is to uncover its significant implications for science and society. We hope to inspire future scholars to push the limits of knowledge and creativity in this fascinating subject.

MATERIAL AND METHODS

This research utilises a comprehensive approach to thoroughly investigate microbial biosynthesis, incorporating several scientific disciplines and approaches to understand the intricacies of discovering natural products and developing drugs. The process involves a thorough examination of existing literature, a complete synthesis of data, a critical analysis of research results, and the integration of scientific viewpoints from other disciplines. Here is an extensive explanation of the methods utilised:

1. Comprehensive Literature Review: The methodology begins with a thorough examination of a broad range of peer-reviewed scientific articles, review papers, and scholarly publications from various research fields including microbiology, biochemistry, synthetic biology, metagenomics, and pharmacology (9). Relevant literature on microbial biosynthesis and its applications is accessed by doing systematic searches on databases such as PubMed, Google Scholar, Web of Science, and specialised repositories.

2. Data Collection and Organisation: Data related to microbial biosynthesis is carefully gathered and arranged. This include data on the variety of microorganisms, the processes by which they produce substances, the techniques used in synthetic biology, the methodology employed in metagenomics, the tactics for exploring new biological resources, the chemical structures of compounds with biological activity, the effects of these compounds on the body, and the breakthroughs in technology within this discipline (10). The data is methodically classified and organised according to its thematic significance to enable further research.

3. Data Synthesis and Analysis: The gathered data undergoes a thorough process of synthesis and analysis to identify patterns, trends, and insights that are pertinent to study on microbial biosynthesis. This entails utilising statistical and qualitative analytic methods to spot repeating patterns, emerging ideas, and noteworthy discoveries throughout the literature (11). An evaluation is carried out to assess the effectiveness, dependability, and possible uses of various procedures, experimental approaches, and research outputs through comparative analysis.

4. Critical Evaluation: An assessment of the synthesised data is conducted to evaluate the quality, validity, and importance of the study findings. This involves closely examining the experimental procedures, experimental design, data interpretation, and statistical analysis used in the research that were examined. Furthermore, the scientific rigour, repeatability, and generalizability of study outputs are carefully evaluated to determine their scientific quality and usefulness to the wider scientific community.

5. Interdisciplinary Integration: The technique incorporates viewpoints from several scientific fields, including as microbiology, biochemistry, synthetic biology, bioinformatics, pharmacology, and biotechnology. The paper seeks to integrate knowledge from several disciplines of study to offer a comprehensive understanding of microbial biosynthesis and its diverse consequences for drug development, industrial biotechnology, and biomedical research.

6. Presentation of Findings: Ultimately, the document presents the synthesised facts and study findings in a logical and organised way. The paper is divided into separate sections, each dedicated to specific aspects of microbial biosynthesis. These aspects include microbial diversity, biosynthetic pathways, synthetic biology applications, metagenomics-driven discovery, structural diversity of bioactive compounds, pharmacological activities, challenges, and future directions (12). The discussion and conclusions in each part are backed by evidence-based facts, scientific literature citations, and illustrated examples.

This paper aims to advance scientific knowledge and innovation in the field of microbial biosynthesis and its applications in drug discovery and biotechnology. It will do so by using a rigorous and comprehensive methodology that includes literature review, data synthesis, critical analysis, interdisciplinary integration, and evidence-based reasoning.

Microbial Diversity and Biosynthetic Pathways

Microbial biosynthesis is a complex process controlled by the various metabolic capacities of microbes. It is a rich source of bioactive chemicals that have different chemical structures and pharmacological effects. This section explores the complex and diverse world of microbes and the processes they use to produce bioactive chemicals with medicinal and biotechnological importance.

A. Bacterial Biosynthesis:

Bacteria, which are found everywhere in different habitats such as soil, water, and the human body, have developed intricate routes to create a wide range of bioactive substances. Bacterial biosynthesis involves the coordinated interaction of biosynthetic enzymes, regulatory components, and environmental signals, resulting in the production of secondary metabolites that have various chemical structures and pharmacological characteristics. (13) Important metabolic pathways in bacteria consist of polyketide synthases (PKSs), nonribosomal peptide synthetases (NRPSs), and hybrid pathways that incorporate components of both. These pathways are accountable for the production of antibiotics, antifungals, anticancer drugs, immunosuppressants, and other biologically active chemicals (14). Prominent instances

of bioactive substances synthesised by bacteria are the macrolide antibiotic erythromycin, which is generated by *Saccharopolyspora erythraea*, the β -lactam antibiotic penicillin derived from *Penicillium* species, and the anticancer drug bleomycin obtained from *Streptomyces verticillus*.

B. Fungal Biosynthesis:

Fungi, which include yeasts, moulds, and mushrooms, are a varied group of eukaryotic microorganisms. They are known for their ability to create a wide range of bioactive substances that have many medicinal and commercial uses. Fungal biosynthesis involves the complex interaction of biosynthetic enzymes, transcription factors, and signalling molecules, which coordinate the generation of secondary metabolites with various chemical structures and pharmacological properties (15). Fungal biosynthesis pathways consist of a diverse range of enzymatic processes, such as polyketide synthases, terpene cyclases, and alkaloid biosynthetic enzymes. These routes produce bioactive chemicals, including antibiotics, antifungals, immunosuppressants, statins, and anticancer drugs. Some beneficial substances synthesised by fungi include penicillin, an antibiotic produced by *Penicillium chrysogenum*, amphotericin B, an antifungal drug produced by *Streptomyces nodosus*, and lovastatin, a statin that lowers cholesterol, produced by *Aspergillus terreus*.

C. Actinomycetal Biosynthesis:

Actinomycetes, which are filamentous bacteria classified under the phylum Actinobacteria, are well-known for their abundant biosynthetic skills and their significant contribution as primary makers of bioactive chemicals. Actinomycetal biosynthesis involves a wide range of biosynthetic pathways, such as PKSs, NRPSs, terpene synthases, and ribosomally synthesised and post-translationally modified peptides (RiPPs) (16). These pathways result in the production of antibiotics, antitumor agents, immunosuppressants, and other biologically active compounds. Actinomycetes have produced a wide range of medically significant antibiotics, including streptomycin, erythromycin, vancomycin, and tetracycline (17). They have also provided anticancer drugs like doxorubicin and bleomycin. The production of secondary metabolites by actinomycetal bacteria is influenced by complex regulatory networks, environmental factors, and genetic factors, which contribute to the diversity and complexity of these metabolites.

D. Marine Microbial Biosynthesis:

Marine microorganisms, such as bacteria, fungus, algae, and cyanobacteria, live in various marine habitats, such as oceans, seas, and estuaries, and play a vital role in the production of a wide range of natural substances. The synthesis of microorganisms in marine environments is influenced by the distinct physicochemical characteristics of these habitats, such as temperature, pressure, salinity, and nutrient availability (18). As a result, a wide range of chemically diverse and biologically potent compounds are produced, which have applications in the fields of pharmaceuticals, agriculture, and industry. Marine microorganisms have produced bioactive chemicals, including antibiotics, antifungals, antivirals, anticancer medicines, and immunomodulators. These molecules often have distinct chemical structures and pharmacological properties. Some bioactive chemicals obtained from marine microorganisms are salinosporamide A, an antibiotic developed from *Salinispora tropica*, ecteinascidin 743, an anticancer drug obtained from *Ecteinascidia turbinata*, and arabinofuranosyladenine, an antiviral molecule derived from *Bacillus* spp (19). The process of marine microbial biosynthesis has potential for uncovering new bioactive chemicals that can be used in medicinal and biotechnological applications.

E. Biosynthetic Pathway Diversity:

Microbial biosynthesis is an intricate process involving enzymatic reactions controlled by several biosynthetic routes. Each pathway is regulated by particular enzyme systems and regulatory mechanisms. Polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) are important in the synthesis of complex polyketide and peptide natural products. They have a wide range of pharmacological actions. Terpene synthases facilitate the formation of various terpenoid compounds by converting isoprenoid precursors like geranyl diphosphate (GPP) and farnesyl diphosphate (FPP) through cyclization (20). On the other hand, alkaloid biosynthetic enzymes control the creation of alkaloids containing nitrogen by carrying out complex enzymatic reactions. Ribosomally synthesised and post-translationally modified peptides (RiPPs) are a distinct group of peptides that are produced from precursor peptides and then changed by enzymes after translation. This process leads to the creation of bioactive peptides with specific functions. Fatty acid synthases (FASs) are essential in the production of lipid-derived natural products, including polyketides and lipopeptides (21). These compounds contribute to the wide range of pharmacological effects seen in microbial metabolites. Understanding the complex biosynthetic pathways not only provides insights into microbial metabolism but also presents opportunities for drug discovery, biotechnology, and industrial applications. This highlights the

significance of comprehending microbial biosynthesis in utilising the extensive potential of natural products for therapeutic and commercial purposes.

Metagenomics and Bioprospecting

Metagenomics and bioprospecting are innovative techniques that are transforming our comprehension of microbial ecosystems and using their unexplored capabilities for diverse purposes, especially in the fields of drug discovery and biotechnology. Metagenomics is a method that does not rely on culturing and involves the thorough examination of microbial communities that are directly collected from various habitats. This technique enables scientists to investigate the genetic makeup and functional variety of these communities, revealing new genes and pathways involved in the production of natural substances (22). Environmental sampling is an essential process in metagenomic investigations, which entails gathering microbial samples from various habitats such as soil, water, sediments, and harsh conditions. These samples give a glimpse into the range of microorganisms present in particular environments, providing vital information about the genetic diversity and possible metabolic capabilities of these microbial communities. Sequencing technologies are crucial in metagenomic investigations since they allow for the efficient examination of microbial genomes and metagenomes. NGS technologies, like Illumina and PacBio, enable the production of large quantities of sequence data, which enables researchers to analyse the genetic makeup of microbial communities with great precision (23). Furthermore, the use of single-molecule real-time sequencing (SMRT) technology, provided by companies like Pacific Biosciences and Oxford Nanopore, allows for the sequencing of lengthy DNA fragments. This capability enables the building of intricate metagenomes and the identification of genetic variants. Sequencing methods enable researchers to determine the taxonomic composition, functional potential, and metabolic pathways of microbial communities, which serves as a basis for bioprospecting endeavours. The discovery of biosynthetic gene clusters (BGCs) is an important component of metagenomic research, which aims to identify and characterise gene clusters that are responsible for the production of natural products. Bioinformatic techniques and algorithms, such as antiSMASH, PRISM, and ClusterFinder, assist in the identification and forecasting of biosynthetic gene clusters (BGCs) within metagenomic datasets (24). These methods utilise sequencing data to detect genes that encode biosynthetic enzymes, regulatory proteins, and transporters that play a role in the creation of secondary metabolites. Researchers might discover potential sources of bioactive substances and investigate their biotechnological uses by analysing metagenomic data for novel biosynthetic gene clusters (BGCs).

Natural product screening is the last stage in the process of bioprospecting. It involves the identification, purification, and analysis of bioactive chemicals found in microbial extracts. High-throughput screening tests, such as antibacterial, anticancer, and enzyme inhibition assays, are used to assess the biological effects of natural materials on specific pathogens or disease models (25). Advanced analytical methods such as mass spectrometry, nuclear magnetic resonance spectroscopy, and X-ray crystallography allow us to determine the structure of bioactive chemicals. This helps us understand their chemical characteristics and how they work. Natural product screening enables researchers to uncover primary substances with medicinal promise and investigate their utilisation in drug development, agricultural biotechnology, and industrial biomanufacturing.

To summarise, metagenomics and bioprospecting provide effective methods for investigating the range of microorganisms and identifying new natural substances with various practical uses. Through the integration of environmental sampling, sequencing technology, BGC discovery, and natural product screening, researchers have the capacity to tap into the immense potential of microbial ecosystems to tackle worldwide issues in healthcare, agriculture, and environmental sustainability. The utilisation of interdisciplinary methodologies shows potential for stimulating innovation and progressing scientific understanding in the domains of microbiology, biotechnology, and pharmaceutical sciences.

Metagenomic Approaches:

Metagenomic approaches refer to the investigation of microbial communities in various environments without the need for culturing. This method provides valuable information about the genetic capabilities and functional variety of microbial ecosystems. Metagenomic methods utilise advanced sequencing technologies, such as next-generation sequencing (NGS) and single-molecule real-time sequencing (SMRT), to analyse the genetic makeup of microbial communities at the genomic level (26). Metagenomic data analysis utilises bioinformatic tools and algorithms to perform taxonomic categorization, functional annotation, and comparative genomics. This enables the discovery of previously unknown biosynthetic gene clusters (BGCs) that encode bioactive chemicals.

Environmental Sampling and Sequencing:

Environmental sampling is a crucial aspect of metagenomic investigations, involving the gathering of microbial samples from various habitats such as soil, water, sediments, and harsh conditions. Sampling tactics are designed to capture the range of microorganisms present in certain habitats. This is achieved via the use of several procedures, including soil coring, water filtering, and sediment collection. After collecting samples, the process of DNA extraction is carried out to separate genomic DNA from microbial populations. This isolated DNA is then analysed using high-throughput sequencing technologies like Illumina, PacBio, or Oxford Nanopore (27). Metagenomic sequencing produces extensive quantities of sequence data, offering valuable information on the taxonomic makeup, functional capabilities, and metabolic pathways of microbial communities.

Biosynthetic Gene Cluster Discovery:

Biosynthetic gene clusters (BGCs) are specific regions in the genome that include genes responsible for the production of specialised metabolites, such as antibiotics, antifungals, antivirals, and anticancer medicines. Metagenomic investigations enable the identification of new biosynthetic gene clusters (BGCs) from microbes that cannot be cultivated, providing a valuable reservoir of genetic data for the exploration of natural products. Bioinformatic techniques, such as antiSMASH, PRISM, and ClusterFinder, are used to identify and annotate biosynthetic gene clusters (BGCs) in metagenomic datasets (28). These methods forecast the existence of genes that encode biosynthetic enzymes, regulatory proteins, and transporters that are involved in the production of secondary metabolites. This helps in determining which biosynthetic gene clusters (BGCs) should be given priority for experimental validation and functional characterization.

Natural Product Screening:

Natural product screening encompasses the process of extracting, purifying, and characterising bioactive chemicals from microbial extracts. Subsequently, these compounds are subjected to biological assessment to determine their pharmacological properties. Metagenomic techniques facilitate the identification of new bioactive substances derived from microbes that cannot be grown in a laboratory, eliminating the requirement for microbial cultivation. High-throughput screening tests, such as antibacterial, anticancer, and enzyme inhibition assays, are used to evaluate the biological effects of natural products on specific pathogens or disease models (29). Furthermore, sophisticated analytical methods including mass spectrometry, nuclear magnetic resonance spectroscopy, and X-ray crystallography are employed to determine the structure of bioactive substances, offering valuable information on their chemical characteristics and modes of operation. To summarise, metagenomics and bioprospecting are effective methods for studying the variety of microorganisms and identifying new natural substances that have potential uses in medicine and biotechnology. Through the use of sophisticated sequencing technologies, bioinformatic algorithms, and high-throughput screening assays, scientists are able to discover valuable resources inside microbial communities. This process facilitates the creation of novel antibiotics, anticancer medicines, and industrial enzymes. The combination of metagenomic techniques and traditional methods for discovering natural products shows potential for tackling worldwide health issues and promoting advancements in the fields of biomedicine and biotechnology.

Synthetic Biology and Pathway Engineering

Synthetic biology and pathway engineering are novel methods used to modify microbial metabolism and biosynthetic pathways in order to produce bioactive molecules with specific qualities and increased yields. This section examines the advanced methods and approaches used in synthetic biology and pathway engineering, such as CRISPR-Cas9-mediated genome editing, route optimisation, heterologous expression systems, and combinatorial biosynthesis.

A. Genome Editing Using CRISPR-Cas9:

The CRISPR-Cas9 technology has brought about a significant transformation in the process of editing genomes in microorganisms. It allows for accurate and effective alterations to be made to microbial genomes, specifically for the purpose of pathway engineering. CRISPR-Cas9 systems employ a guide RNA (gRNA) to precisely target particular locations in the genome, guiding the Cas9 nuclease to create double-stranded breaks (DSBs) at the intended places (30). These double-strand breaks (DSBs) initiate biological processes for repairing DNA, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), which enable gene knockout, knock-in, or precise base editing. CRISPR-Cas9-mediated genome editing is used in microbial biosynthesis to manipulate biosynthetic gene clusters (BGCs), regulatory elements, and metabolic pathways. This modification aims to increase the production of certain chemicals. This technique facilitates the modification of microbial hosts to enhance their ability to produce useful substances, which opens up opportunities for creating new medical treatments, biofuels, and specialised chemicals.

B. Optimisation of the pathway

Pathway optimisation is the meticulous adjustment of metabolic pathways and biosynthetic routes to achieve the highest possible yield of target metabolites. This method involves the systematic design and manipulation of enzyme kinetics, substrate specificity, cofactor availability, and metabolic fluxes to improve the efficiency of a route and increase the amount of desired products. Computational methods, such as flux balance analysis (FBA), dynamic metabolic modelling, and machine learning algorithms, assist in predicting and optimising metabolic pathways in microbial hosts (31). Furthermore, the use of directed evolution and protein engineering methods enables the enhancement of enzyme efficiency and selectivity towards substrates, hence enhancing the overall productivity of the system. Pathway optimisation methodologies are utilised in many metabolic engineering applications, such as the synthesis of medicines, biofuels, and industrial chemicals, to attain economically feasible and environmentally sustainable bioprocesses.

C. Heterologous Expression Systems:

Heterologous expression systems entail the transfer and expression of exogenous genes or pathways in a recipient organism to generate specific chemicals. Microbial hosts, such as *Escherichia coli*, *Saccharomyces cerevisiae*, and filamentous fungus, are often used as platforms for expressing foreign genes because of their well-studied genetics, rapid growth rates, and ease of genetic modification (32). Heterologous expression systems facilitate the synthesis of intricate natural compounds from organisms that are not their natural hosts. This overcomes the constraints of biosynthesis and broadens the range of chemical variations that may be produced for industrial purposes. Advanced methods in synthetic biology, such as synthetic promoters, ribosome binding sites (RBSs), and gene assembly techniques, make it easier to control and improve the expression of foreign genes, resulting in higher amounts and production rates of desired substances. Heterologous expression systems are utilised in the creation of medicines, enzymes, nutraceuticals, and specialised compounds, which contribute to advancements in biomanufacturing and biotechnology (33).

D. Combinatorial Biosynthesis:

Combinatorial biosynthesis refers to the process of organising and altering biosynthetic gene clusters (BGCs) in order to create a wide range of natural products that have improved characteristics. This method exploits the modularity and versatility of biosynthetic enzymes to create new substances by rearranging biosynthetic building pieces in various combinations. Synthetic biology approaches, including DNA assembly procedures, genetic recombination techniques, and pathway engineering tactics, allow for the creation of collections of natural product analogues with modified structures and biological activity (34). High-throughput screening assays and analytical techniques expedite the identification and characterisation of lead compounds with desirable qualities, hastening the development of new medicines, agrichemicals, and functional components. Combinatorial biosynthesis has possibilities for increasing the range of chemical compounds found in natural products and identifying bioactive substances with enhanced pharmacological properties and economic viability. To summarise, synthetic biology and pathway engineering provide effective methods for designing, optimising, and producing bioactive chemicals by precisely manipulating microbial metabolism and biosynthetic pathways. CRISPR-Cas9 technology, pathway optimisation, heterologous expression systems, and combinatorial biosynthesis are advanced methods used to modify microbial hosts for improved bioproduction and biotechnological applications (35). These methods stimulate creativity and progress in the fields of medication development, production of biological substances, and environmentally-friendly biological processing, influencing the future of biotechnology and pharmaceutical sciences.

Structural Diversity and Pharmacological Activities

Natural compounds originating from microbial biosynthesis has inherent features of structural variety and pharmacological activity. These products include polyketides, nonribosomal peptides, terpenoids, and alkaloids. This section examines the extensive variety of chemical structures displayed by these categories of natural compounds and their broad spectrum of pharmacological activities.

A. Polyketides:

Polyketides are a varied group of natural substances that are produced by polyketide synthases (PKSs) by the combination of basic building components, usually malonyl-CoA, to create chains of polyketides. These compounds exhibit a wide range of structural variety, varying from simple linear chains to intricate macrocycles, and have several pharmacological actions. Polyketides are highly effective in treating bacterial infections, fungal infections, cancer, and suppressing the immune system, which makes them useful in the field of medicine (36). Some notable instances of chemicals generated from polyketides

include the macrolide antibiotic erythromycin, the antifungal agent amphotericin B, and the anticancer medicine epothilone.

B. Nonribosomal Peptides:

Nonribosomal peptides are a category of organic compounds produced by nonribosomal peptide synthetases (NRPSs) by the step-by-step combination of amino acid components. These peptides have varied chemical structures, frequently include uncommon amino acids and changed peptide bonds, and demonstrate a broad spectrum of pharmacological effects. Nonribosomal peptides exhibit medicinal promise as antibiotics, antivirals, immunosuppressants, and enzyme inhibitors. Nonribosomal peptide-derived compounds encompass many substances such as the antibiotic gramicidin S, the immunosuppressant cyclosporine, and the antifungal agent fusarin C.

C. Terpenoids:

Terpenoids are a vast and varied group of natural substances that are produced by terpene synthases from isoprenoid precursors. These molecules include a variety of chemical structures, such as mono-, sesqui-, di-, tri-, and tetraterpenoids, and have a wide range of pharmacological effects. Terpenoids exhibit a wide range of biological actions, including antibacterial, antiviral, anti-inflammatory, and anticancer properties (37). Terpenoid-derived compounds such as artemisinin, paclitaxel, and menthol are examples of substances that have been synthesised from terpenoids. These compounds have various uses, including being an antimalarial medication, an anticancer agent, and an antibacterial chemical, respectively.

D. Alkaloids:

Alkaloids are organic compounds that include nitrogen and are produced by plants, fungi, and bacteria through intricate biosynthetic processes. These compounds have a variety of chemical structures, frequently include heterocyclic rings and nitrogen atoms, and demonstrate a broad spectrum of pharmacological actions. Alkaloids have medicinal properties and may be used as pain relievers, anti-inflammatory drugs, drugs that affect the mind, and drugs that affect the cardiovascular system (38). This makes them highly important in medicine. Alkaloid-derived chemicals encompass several substances, such as the pain-relieving morphine, the anti-inflammatory medication quinine, and the mind-altering alkaloid caffeine.

E. Pharmacological Properties:

The chemical structures, molecular targets, and biological activities of natural products all have an impact on their pharmacological qualities. Polyketides, nonribosomal peptides, terpenoids, and alkaloids possess a wide range of pharmacological characteristics, such as antibacterial, antiviral, anticancer, anti-inflammatory, and immunomodulatory effects. These molecules engage with a range of molecular targets, such as enzymes, receptors, ion channels, and signalling pathways, to regulate cellular activities and physiological processes (39). Natural products possess a wide range of structural variations, which enhances their ability to have diverse pharmacological effects and potential for therapeutic applications. As a result, they are highly beneficial in the field of drug discovery and development. To summarise, natural products originating from microbial biosynthesis are characterised by their structural variety and pharmacological activity. These products include polyketides, nonribosomal peptides, terpenoids, and alkaloids. These compounds have a broad spectrum of pharmacological characteristics, which is a result of their varied chemical compositions and biological functions. Comprehending the pharmacological characteristics of natural substances is crucial for harnessing their healing capabilities and progressing in the field of medicine and innovation.

Challenges and Future Directions

The use of microbial biosynthesis and natural product discovery has great potential in meeting diverse societal demands. However, there are several hurdles that need to be overcome in order to effectively harness their capabilities. This section examines the primary obstacles encountered in the field and presents some strategies for surmounting these issues in the future.

A. Optimising fermentation:

An essential obstacle in microbial biosynthesis is the need to optimise fermentation processes in order to increase the yield of desired chemicals. The growth of microorganisms and the synthesis of metabolites are greatly affected by several factors during fermentation, including pH, temperature, substrate availability, and oxygenation (40). Fermentation optimisation tactics encompass the development and use of customised culture procedures, metabolic engineering methods, and bioprocess optimisation techniques to achieve the highest possible product yields while minimising production costs. Furthermore, the progress in bioreactor design, monitoring, and control systems is crucial for the expansion of microbial fermentation processes in industrial manufacturing.

B. Pathway Elucidation:

Unraveling biosynthetic pathways and comprehending the molecular processes that drive natural product biosynthesis continue to be important obstacles in microbial biosynthesis. Although bioinformatic tools and genome mining technologies have made it easier to find biosynthetic gene clusters (BGCs), it is still difficult to determine the function of biosynthetic enzymes and pathway intermediates. In order to understand the process of natural product biosynthesis, future research will need to use integrated multi-omics methodologies, such as genomics, transcriptomics, proteomics, and metabolomics (41). These approaches will help to untangle the intricate interactions between genes, enzymes, and metabolites. These extensive datasets will offer valuable information on the control of pathways, metabolic fluxes, and targets for pathway engineering to enhance the synthesis of natural products.

C. Scalability of Production:

The scalability of microbial biosynthesis for industrial production poses practical issues in terms of process scalability, repeatability, and cost-effectiveness. Although laboratory-scale fermentation systems may show promising outcomes, scaling up to large-scale production often necessitates substantial optimisation and validation endeavours. In order to achieve effective and economically feasible production, it is crucial to carefully evaluate factors such as substrate availability, fermentation kinetics, downstream processing, and product purification procedures (42). Furthermore, it is crucial to create bioprocessing technologies that are sustainable and ecologically friendly in order to reduce the ecological impact of microbial biomanufacturing.

D. Translational Research:

Translational research refers to the process of using scientific findings and knowledge from basic research to develop practical applications and interventions that can benefit patients and society. The translation of laboratory findings into practical applications is a major obstacle in the fields of microbial biosynthesis and natural product discovery. To facilitate the transition from basic research to commercialization, it is essential to foster cooperation among different disciplines, establish effective procedures for technology transfer, and form strategic alliances including academia, industry, and regulatory authorities. Translational research should prioritise the validation of the effectiveness, safety, and ability to be expanded of products produced from microorganisms (43). This should be done through preclinical and clinical studies, regulatory approval procedures, and strategies to enter the market. Furthermore, it is crucial to promote the development of entrepreneurship and innovation ecosystems in order to facilitate the commercialization of microbial biotechnologies and their integration into various businesses and healthcare sectors.

E. Regulatory Considerations:

The commercialization of microbial-derived products is significantly hindered by the complex task of navigating regulatory frameworks and meeting compliance requirements. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce strict regulations to ensure the safety, quality, and effectiveness of medicines, biologics, and biotechnology goods. Microbial biotechnologies must comply with Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and other regulatory standards to guarantee the quality of their products and meet regulatory requirements (44). Moreover, it is crucial to consider and discuss ethical, legal, and sociological issues associated with microbial biotechnology, including intellectual property rights, biosecurity, and environmental effects, in order to promote public confidence and approval of these technologies. To summarise, overcoming the difficulties in microbial biosynthesis and natural product discovery necessitates the cooperation of experts from many fields, the development of advanced technology, and careful strategic thinking. To fully harness the capabilities of microbial biotechnologies in addressing global health, environmental, and economic challenges, it is crucial to overcome obstacles and make progress in areas such as fermentation optimisation, pathway elucidation, scalability of production, translational research, and regulatory considerations (45). Future advancements in microbial biosynthesis should prioritise the development of environmentally friendly and economically efficient bioprocessing technologies, expediting the transformation of scientific findings into commercially viable products, and promoting responsible innovation and ethical management in the sector.

CONCLUSION

To summarise, the study of microbial biosynthesis provides an opportunity to delve into the captivating realm of nature's molecular machinery, providing valuable knowledge about the complex mechanisms involved in the creation of bioactive substances. During our exploration, we have discovered a large collection of different types of microorganisms, revealing the extensive amount of genetic capabilities that

exist inside these communities of microorganisms. The wide range of chemical compounds, including polyketides, terpenoids, nonribosomal peptides, and alkaloids, display a variety of structures and have significant pharmacological properties. This highlights their significance as valuable sources for developing therapeutic drugs and advancements in biotechnology. Our work has not only provided insight into the intricate nature of microbial biosynthetic pathways, but it has also shown potential opportunities for drug development, biomanufacturing, and environmental stewardship. The use of metagenomic techniques and the search for new resources have broadened our knowledge, allowing us to find new groups of genes responsible for producing substances and potential products from untapped microbial environments (46). Furthermore, the field of synthetic biology and route engineering has provided us with the ability to enhance and expand microbial production processes, leading to advancements in bioprocessing and industrial biotechnology. Looking into the future, the consequences of our discoveries are significant, having extensive effects on human health, agriculture, and environmental sustainability. Discovering new natural compounds shows potential for tackling worldwide health issues, fighting against infectious illnesses, and reducing the risk of antibiotic resistance (47). Furthermore, the incorporation of microbial biotechnologies into sustainable bioprocesses presents possibilities for diminishing our dependence on fossil fuels, mitigating environmental contamination, and advocating for a more sustainable future for future generations. To conclude, the study of microbial biosynthesis involves continuous inquiry and discovery, driven by the limitless curiosity of human beings. As we further explore the complexities of microbial metabolism and biosynthetic pathways, it is important that we maintain our dedication to scientific investigation, ethical responsibility, and prudent advancement. Through the use of microbial biotechnology, we may fully exploit the inherent capabilities of nature's molecular resources, leading to a more promising and environmentally-friendly future for everyone.

Summary of Key Findings:

During this extensive investigation of microbial biosynthesis, several significant discoveries have been made. We have explored the complex realm of microbial variety, revealing a wide range of species that have the ability to produce bioactive substances that might be used for medicinal purposes. Through the examination of biosynthetic routes such as polyketides, nonribosomal peptides, terpenoids, and alkaloids, we have discovered the impressive range of structures and medicinal properties displayed by these organic compounds. Metagenomic techniques and efforts to explore biological resources have yielded important knowledge about communities of microorganisms, enabling the identification of new groups of genes responsible for producing useful substances and potential candidates for natural products. Moreover, progress in the field of synthetic biology and route engineering has facilitated the process of improving and producing bioactive chemicals on a larger scale, which has led to significant improvements in drug development and biotechnology.

Implications and Future Directions:

The ramifications of our discoveries have far-reaching effects outside the scope of scientific investigation, with substantial consequences for drug research, healthcare, and biotechnological advancement. Discovering new natural compounds with medicinal properties offers hope for tackling medical challenges, fighting against drug-resistant microorganisms, and enhancing human well-being. In addition, the incorporation of advanced technologies like CRISPR-Cas9-mediated genome editing, high-throughput screening, and combinatorial biosynthesis provides new opportunities for the advancement of next-generation therapies and industrial bioproducts. Future endeavours in microbial biosynthesis should give priority to the development of environmentally friendly bioprocessing techniques, make use of advancements in multi-omics technology to better understand metabolic pathways, and tackle regulatory and ethical concerns to enable the practical use of new findings.

Closing Remarks:

Microbial biosynthesis is an area of scientific inquiry and innovation that offers several prospects for enhancing human health and environmental sustainability. In conclusion, As we further explore the intricacies of microbial metabolism and biosynthetic pathways, it is crucial that we maintain a strong dedication to doing research responsibly, practicing ethical stewardship, and fostering collaborative relationships. Through the use of microbial biotechnology, we may lay the foundation for a more promising future marked by innovative medical treatments, environmentally-friendly industrial processes, and a more comprehensive comprehension of the complex interconnectedness of living organisms. Let us explore and create new things together, using the amazing process of microbial biosynthesis as our guide.

REFERENCES

1. Sharma, S. R., Sharma, R., & Kar, D. (2022). Novel Microbial Compounds as a Boon in Health Management. In *Biotechnological Advances for Microbiology, Molecular Biology, and Nanotechnology* (pp. 77-118). Apple Academic Press.
2. Selim, M. S. M., Abdelhamid, S. A., & Mohamed, S. S. (2021). Secondary metabolites and biodiversity of actinomycetes. *Journal of Genetic Engineering and biotechnology*, 19(1), 72.
3. Orsi, W. D. (2018). Ecology and evolution of seafloor and subseafloor microbial communities. *Nature Reviews Microbiology*, 16(11), 671-683.
4. Galm, U., & Shen, B. (2006). Expression of biosynthetic gene clusters in heterologous hosts for natural product production and combinatorial biosynthesis. *Expert opinion on drug discovery*, 1(5), 409-437.
5. Salomon, C. E., Magarvey, N. A., & Sherman, D. H. (2004). Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine natural product drug discovery. *Natural product reports*, 21(1), 105-121.
6. Cao, Z., Yu, J., Wang, W., Lu, H., Xia, X., Xu, H., ... & Zhang, L. (2020). Multi-scale data-driven engineering for biosynthetic titer improvement. *Current Opinion in Biotechnology*, 65, 205-212.
7. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. *Nature reviews Drug discovery*, 20(3), 200-216.
8. Bills, G. F., & Gloer, J. B. (2016). Biologically active secondary metabolites from the fungi. *Microbiology spectrum*, 4(6), 10-1128.
9. Kumar, P., Sinha, R., & Shukla, P. (2022). Artificial intelligence and synthetic biology approaches for human gut microbiome. *Critical Reviews in Food Science and Nutrition*, 62(8), 2103-2121.
10. García-Cañas, V., Simó, C., León, C., & Cifuentes, A. (2010). Advances in Nutrigenomics research: novel and future analytical approaches to investigate the biological activity of natural compounds and food functions. *Journal of pharmaceutical and biomedical analysis*, 51(2), 290-304.
11. Sullivan, C. J., McGloin, J. M., Ray, J. V., & Caudy, M. S. (2009). Detecting specialization in offending: comparing analytic approaches. *Journal of Quantitative Criminology*, 25, 419-441.
12. Zhang, M. M., Qiao, Y., Ang, E. L., & Zhao, H. (2017). Using natural products for drug discovery: the impact of the genomics era. *Expert opinion on drug discovery*, 12(5), 475-487.
13. Li, Y., Kong, D., Fu, Y., Sussman, M. R., & Wu, H. (2020). The effect of developmental and environmental factors on secondary metabolites in medicinal plants. *Plant Physiology and Biochemistry*, 148, 80-89.
14. Georgopapadakou, N. H., & Walsh, T. J. (1996). Antifungal agents: chemotherapeutic targets and immunologic strategies. *Antimicrobial agents and chemotherapy*, 40(2), 279-291.
15. Gantet, P., & Memelink, J. (2002). Transcription factors: tools to engineer the production of pharmacologically active plant metabolites. *Trends in Pharmacological Sciences*, 23(12), 563-569.
16. Carretero Molina, D. (2024). Expanding the chemical space of microbial specialized metabolites: structure elucidation and biosynthesis of novel bioactive natural products from actinomycetes
17. Chaudhary, H. S., Soni, B., Shrivastava, A. R., & Shrivastava, S. (2013). Diversity and versatility of actinomycetes and its role in antibiotic production. *Journal of Applied Pharmaceutical Science*, 3(8), S83-S94.
18. Das, S., Lyla, P. S., & Khan, S. A. (2006). Marine microbial diversity and ecology: importance and future perspectives. *Current science*, 1325-1335.
19. Ghareeb, M. A., Tammam, M. A., El-Demerdash, A., & Atanasov, A. G. (2020). Insights about clinically approved and Preclinically investigated marine natural products. *Current Research in Biotechnology*, 2, 88-102
20. Nagegowda, D. A., & Gupta, P. (2020). Advances in biosynthesis, regulation, and metabolic engineering of plant specialized terpenoids. *Plant Science*, 294, 110457.
21. Cameron Coates, R., Trentacoste, E., & Gerwick, W. H. (2013). Bioactive and novel chemicals from microalgae. *Handbook of microalgal culture: applied phycology and biotechnology*, 504-531.
22. Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafiqat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015). Sequencing and beyond: integrating molecular 'omics' for microbial community profiling. *Nature Reviews Microbiology*, 13(6), 360-372.
23. Hodkinson, B. P., & Grice, E. A. (2015). Next-generation sequencing: a review of technologies and tools for wound microbiome research. *Advances in wound care*, 4(1), 50-58.
24. Alanjary, M. (2018). Developing genome mining tools for the discovery of bioactive secondary metabolites (Doctoral dissertation, Universität Tübingen).
25. Lage, O. M., Ramos, M. C., Calisto, R., Almeida, E., Vasconcelos, V., & Vicente, F. (2018). Current screening methodologies in drug discovery for selected human diseases. *Marine drugs*, 16(8), 279
26. Sharma, A., Vashist, J., & Shrivastava, R. (2021). Next-generation omics technologies to explore microbial diversity. In *Microbes in Land Use Change Management* (pp. 541-563). Elsevier.
27. Ambardar, S., Gupta, R., Trakroo, D., Lal, R., & Vakhlu, J. (2016). High throughput sequencing: an overview of sequencing chemistry. *Indian journal of microbiology*, 56, 394-404.
28. Gupta, V. K., Bakshi, U., Chang, D., Lee, A. R., Davis III, J. M., Chandrasekaran, S., ... & Sung, J. (2022). TaxiBGC: a taxonomy-guided approach for profiling experimentally characterized microbial biosynthetic gene clusters and secondary metabolite production potential in metagenomes. *Msystems*, 7(6), e00925-22.
29. Lage, O. M., Ramos, M. C., Calisto, R., Almeida, E., Vasconcelos, V., & Vicente, F. (2018). Current screening methodologies in drug discovery for selected human diseases. *Marine drugs*, 16(8), 279.

30. Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., ... & Joung, J. K. (2015). GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nature biotechnology*, 33(2), 187-197.
31. Patra, P., Disha, B. R., Kundu, P., Das, M., & Ghosh, A. (2023). Recent advances in machine learning applications in metabolic engineering. *Biotechnology Advances*, 62, 108069.
32. Conner, A. J., & Jacobs, J. M. (1999). Genetic engineering of crops as potential source of genetic hazard in the human diet. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 443(1-2), 223-234.
33. Vasilev, N. (2022). Medicinal Plants: Guests and Hosts in the Heterologous Expression of High-Value Products. *Planta Medica*, 88(13), 1175-1189.
34. Li, G., & Lou, H. X. (2018). Strategies to diversify natural products for drug discovery. *Medicinal research reviews*, 38(4), 1255-1294
35. Galm, U., & Shen, B. (2006). Expression of biosynthetic gene clusters in heterologous hosts for natural product production and combinatorial biosynthesis. *Expert opinion on drug discovery*, 1(5), 409-437.
36. Pathakumari, B., Liang, G., & Liu, W. (2020). Immune defence to invasive fungal infections: A comprehensive review. *Biomedicine & Pharmacotherapy*, 130, 110550.
37. Yang, W., Chen, X., Li, Y., Guo, S., Wang, Z., & Yu, X. (2020). Advances in pharmacological activities of terpenoids. *Natural Product Communications*, 15(3), 1934578X20903555.
38. Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., ... & Li, X. (2018). Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. *International journal of biological sciences*, 14(3), 341.
39. Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., ... & CGTP Collaborators. (2015). The concise guide to PHARMACOLOGY 2015/16: Catalytic receptors. *British Journal of Pharmacology*, 172(24), 5979-6023.
40. Manpreet, S., Sawraj, S., Sachin, D., Pankaj, S., & Banerjee, U. C. (2005). Influence of process parameters on the production of metabolites in solid-state fermentation. *Malaysian Journal of Microbiology*, 2(1), 1-9.
41. Palazzotto, E., & Weber, T. (2018). Omics and multi-omics approaches to study the biosynthesis of secondary metabolites in microorganisms. *Current opinion in microbiology*, 45, 109-116.
42. Kosseva, M. R., & Rusbandi, E. (2018). Trends in the biomanufacture of polyhydroxyalkanoates with focus on downstream processing. *International journal of biological macromolecules*, 107, 762-778.
43. Sorkin, B. C., Kuszak, A. J., Bloss, G., Fukagawa, N. K., Hoffman, F. A., Jafari, M., ... & Pauli, G. F. (2020). Improving natural product research translation: From source to clinical trial. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*, 34(1), 41.
44. Special Programme for Research, Training in Tropical Diseases, & World Health Organization. (2009). Handbook: good laboratory practice (GLP): quality practices for regulated non-clinical research and development. World Health Organization.
45. National Research Council, Division on Earth, Life Studies, Board on Life Sciences, Board on Chemical Sciences, Committee on Industrialization of Biology, & A Roadmap to Accelerate the Advanced Manufacturing of Chemicals. (2015). *Industrialization of biology: A roadmap to accelerate the advanced manufacturing of chemicals*.
46. Genilloud, O. (2014). The re-emerging role of microbial natural products in antibiotic discovery. *Antonie Van Leeuwenhoek*, 106, 173-188.
47. Álvarez-Martínez, F. J., Barraji n-Catal n, E., & Micol, V. (2020). Tackling antibiotic resistance with compounds of natural origin: A comprehensive review. *Biomedicines*, 8(10), 405.

Copyright:   2024 Author. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.